Program

Each session will feature 15-minute presentations coupled with 5-minute Q&As and ending with 30-minute panel discussions. We highly encourage participants to review the e-posters from our investigators before the actual live event (e-posters will be available for review the week of October 4).

All times below are in US Eastern Time – to review times in your own time zone, please use the green buttons below.

A PDF version of the program will be made available soon.

PROGRAM AT-A-GLANCE

See DAY 1 date/times in your time zone See DAY 2 date/times in your time zone See DAY 3 date/times in your time zone

PROGRAM AT-A-GLANCE

Monday, October 11, 2021 – all times in US Eastern Time

Session/Lecture

10:00 ET

Welcome & Introductory Notes

10:05

Session I
Part 1: ATN Biomarkers
Part 2: Ocular Approaches and Emerging Protein Biomarkers of ADRD
5 min for questions at the end of each talk

10:05

Session Overview

10:10

Plasma Amyloid Beta Ratio as a Diagnostic Test for Alzheimer-related Amyloid Pathology

10:30

Comparative Analytical Performance of Multiple Plasma Amyloid-beta Assays and their Relationship to Amyloid PET

10:50

Tau and p-tau as Alzheimer Biomarkers - Assays, Methodological Aspects and Clinical Performance

11:10

E-poster Vignettes

E-poster: Validation and Commercialization of a Novel Blood-based, Ultra-multiplex Laboratory Developed Test (LDT) for the Prediction of Cerebral Amyloid Status before Clinical Onset of Dementia

E-poster: Towards an Easy Plasma pTau 181 Detection Using the LUMIPULSE G Platform

11:20

Questions and Discussion

11:40

Lunch Break and Networking

12:00

Session Overview

12:05

Investigating Novel Neuro-retinal Biomarkers for Alzheimer’s Disease

12:25

RetiSpec’s Hyperspectral Imaging System: A Novel Approach to Retinal-based Detection of Alzheimer’s Disease

12:45

E-poster Vignette

E-poster: Identifying an Ophthalmic Combinatorial Biomarker of Early Alzheimer’s Disease Using Deep Learning

12:50

Questions and Discussion

13:10

Break

13:20

The Role of Plasma Contact System Activation in Alzheimer's Disease Pathophysiology

13:40

On-Chip Detection of Alzheimer’s Disease Biomarkers in Extracellular Vesicles Isolated from Peripheral Blood

14:00

Validation of Blood-based Biomarkers for the Detection of Brain Amyloid Accumulation

14:20

E-poster Vignettes

E-poster: Blood-based Detection of Alzheimer’s Disease through Single-Cell Peripheral Immunoprofiling

E-poster: Validation of Alzheimer’s Disease Biomarkers and Methods of Recruitment of a Racially Diverse Study Population

14:30

Questions and Discussion

15:00

DAY 1: CLOSING REMARKS

15:05

End of Day 1

Chair/Speaker

10:00 ET

Howard Fillit, MD, Alzheimer’s Drug Discovery Foundation

10:05

Part 1 Chair: Robert Dean, MD, PhD, Robert A. Dean Consulting
Part 2 Chair: Anka Ehrhardt, PhD, CHDI

10:05

Robert Dean, MD, PhD, Robert A. Dean Consulting
Anka Ehrhardt, PhD, CHDI

10:10

Henrik Zetterberg, MD, PhD, University of Gothenburg

10:30

Wesley Horton, PhD, Foundation for the National Institutes of Health
Steve Zicha, PhD, Takeda

10:50

Kaj Blennow, MD, PhD, University of Gothenburg

11:10

E-poster Vignettes

Leyla Anderson, MD, PhD, D(ABMLI), NeuroVision Imaging Inc.

Manu Vandijck, FujireBio

11:20

Moderator: Robert Dean, MD, PhD, Robert A. Dean Consulting

11:40

Lunch Break and Networking

12:00

Anka Ehrhardt, PhD, CHDI

12:05

Thomas MacGillivray, PhD, University of Edinburgh

12:25

Eliav Shaked, MSc, Retispec
Catherine Bornbaum, PhD, MBA, Retispec

12:45

E-poster Vignette

Cecilia Lee, MD, University of Washington

12:50

Moderator: Anka Ehrhardt, PhD, CHDI

13:10

Break

13:20

Erin Norris, PhD, The Rockefeller University

13:40

Amber Murray, PhD, Biological Dynamics

14:00

Blaine Roberts, PhD, Emory University
Leyla Anderson, MD, PhD, NeuroVision

14:20

E-poster Vignettes

Thanaphong (Joe) Phongpreecha, PhD, Stanford University
Thomas Montine, MD, Stanford University

Diana Kerwin, MD, GAP Innovations, PBC

14:30

Moderators: Robert Dean, MD, PhD, Robert A. Dean Consulting
Anka Ehrhardt, PhD, CHDI

15:00

Robert Dean, MD, PhD, Robert A. Dean Consulting
Anka Ehrhardt, PhD, CHDI

15:05

End of Day 1

Tuesday, October 12, 2021 – all times in US Eastern Time

Session/Lecture

10:00

Session II
Part 1: Peripheral Molecular Biomarkers of ADRD
Part 2: Misfolded Proteins and Biomarkers of FTD
5 min for questions at the end of each talk

10:00

Welcome & Introductory Notes

10:05

A Liquid Biopsy for Alzheimer’s Disease

10:25

Non-coding RNA Based Biomarkers for the Diagnosis and Therapy of Alzheimer’s Disease

10:45

Blood-Based miRNA Diagnostics of Alzheimer’s Disease

11:05

Mitoepigenetic Analysis in Blood Samples from MCI Patients to Identify their Progression to Alzheimer’s Disease

11:25

Plasma Cell-Free RNA as an Alzheimer's Disease Non-invasive Biomarker

11:45

Circulating Brain-Enriched microRNAs as Peripheral Biomarkers of Neurodegeneration

12:05

Use of Aptamarkers to Predict Brain Amyloid Deposition

12:25

Questions and Discussion

12:55

Lunch Break and Networking

13:15

Session Overview

13:20

Advancing Differential Diagnosis of Dementias by Direct Detection of Prion Like Particles

13:40

Using Large Data Approaches to Diagnose and Drug Dementia

14:00

The Neurofilament Surveillance Project (NSP): Lessons Learned during Year 1 of our Blood Biomarker Study in Familial Frontotemporal Lobar Degeneration

14:20

E-poster Vignettes

E-poster: Plasma Pathologic TDP-43 as a Biomarker for FTLD-TDP

E-poster: Analytical Validation of Neurofilament Light and Phospho-Neurofilament Heavy Biomarkers for Patient Selection in Disease Modifying Clinical Trials for Pre-Symptomatic Familial Frontotemporal Degeneration

14:30

Questions and Discussion

15:00

DAY 2: CLOSING REMARKS

15:05

Conference continues later in the day Tuesday/early Wednesday morning for Far East Asia/Australia

Chair/Speaker

10:00

Part 1 Chair: James Gallarda, PhD, Dx Consultancy
Part 2 Chair: Penny Dacks, PhD, AFTD

10:00

James Gallarda, PhD, Dx Consultancy

10:05

Asael Lubotzky, MD, PhD, Hebrew University

10:25

Hüseyin FIRAT, MD, PhD, Amoneta Diagnostics S.A.S.

10:45

Bruno Steinkraus, PhD, Hummingbird Diagnostics GmbH

11:05

Marta Barrachina, PhD, ADmit Therapeutics S.L.
Marta Blanch, PhD, ADmit Therapeutics S.L.

11:25

Laura Ibanez, PhD, Washington University

11:45

Kira Sheinerman, PhD, Diamir Biosciences

12:05

Gregory Penner, PhD, NeoNeuro

12:25

Moderator: James Gallarda, PhD, Dx Consultancy

12:55

Lunch Break and Networking

13:15

Penny Dacks, PhD, AFTD

13:20

Russell Lebovitz, PhD, Amprion Inc.

13:40

Judith Steen, PhD, Boston Children’s Hospital

14:00

Rachel Acuña-Narvaez, JD, Bluefield Project to Cure FTD

14:20

E-poster Vignettes

Qinwen Mao, MD, PhD, University of Utah

Wesley Horton, PhD, Foundation for the National Institutes of Health
Danielle Graham, PhD, Biogen

14:30

Moderator: Penny Dacks, PhD, AFTD

15:00

James Gallarda, PhD, Dx Consultancy
Penny Dacks, PhD, AFTD

15:05

Conference continues later in the day Tuesday/early Wednesday morning for Far East Asia/Australia

Tuesday, October 12, 2021 – all times in US Eastern Time

Session/Lecture

18:00

Session II
Part 3: Updates from the Pacific Rim
5 min for questions at the end of each talk

18:00

Welcome & Introductory Notes

18:05

Retinal Imaging Biomarkers of Alzheimer’s Disease

18:25

E-poster Vignette

E-poster: Plasma Neuroinflammatory Biomarkers for the Diagnosis of Dementia Subtypes

18:30

Federated Learning for Detecting Digital Biomarker of Alzheimer’s Disease

18:50

Questions and Discussion

19:10

DAY 2: CLOSING REMARKS

19:15

End of Day 2

Chair/Speaker

18:00

Part 3 Chair: Tetsuyuki Maruyama, PhD, Alzheimer’s Disease Data Initiative

18:00

Tetsuyuki Maruyama, PhD, Alzheimer’s Disease Data Initiative

18:05

Peter van Wijngaarden, MBBS, PhD, Center for Eye Research Australia

18:25

E-poster Vignette

Matthew Pase, PhD, Monash University

18:30

Guoliang Xing PhD, Chinese University of Hong Kong

18:50

Moderator: Tetsuyuki Maruyama, PhD, Alzheimer’s Disease Data Initiative

19:10

Tetsuyuki Maruyama, PhD, Alzheimer’s Disease Data Initiative

19:15

End of Day 2

Wednesday, October 13, 2021 – all times in US Eastern Time

Session/Lecture

9:00

Meet with the DxA Team and Steering Committee (drop by in the breakout rooms to meet virtually with the program officers)

10:00

Session III
Digital Biomarkers
5 min for questions at the end of each talk

10:00

Welcome & Introductory Notes

10:05

Experimental Protocol for Developing Novel Virtual Reality Method to Distinguish Apathy from Depression in the Context of Dementia

10:25

Smartphone-based Learning and Memory Assessment (Lila^TM): Beta Application Pilot Evaluation

10:45

Alzheimer’s Disease Digital Biomarker Discovery: Framingham Cognitive Aging and Dementia Study

11:05

Collaborative Benchmarking and Validation of Digital Biomarkers

11:25

E-poster Vignettes

E-poster: EARDREAM--Towards an integral and sensitive neurophysiological risk biomarker for asymptomatic detection of Alzheimer’s disease

E-poster: PROSPECT-AD--Population-based scReening Over SPEech for Clinical Trials in AD

E-poster: Early Detection of Neurodegenerative Diseases Initiative

E-poster: Speech & Language Consortium

E-poster: Digital Neuro Signatures to Detect Subtle Alterations in the Early Stages of Alzheimer’s Disease: Altoida's Micro-movements for Preclinical AD

E-poster: Rising to the Challenge: Remote Cognitive Assessment for Early Stage Dementia

E-poster: Fixational Eye Motion as a Biomarker for Mild Cognitive Impairment

11:45

Questions and Discussion

12:15

CONCLUDING REMARKS

12:30

End of Meeting

Chair/Speaker

9:00

Meet with the DxA Team and Steering Committee (drop by in the breakout rooms to meet virtually with the program officers)

10:00

Chair: Lampros Kourtis, PhD, Circadic

10:00

Lampros Kourtis, PhD, Circadic

10:05

Ramit Ravona-Springer, MD, Sheba Medical Centre

10:25

Chris Edgar, PhD, Cogstate Ltd

10:45

Rhoda Au, PhD, Boston University

11:05

Larsson Omberg, PhD, Sage Bionetworks

11:25

E-poster Vignettes

Caroline Lustenberger, PhD, ETH Zuerich

Nicklas Linz, ki elements

Zoe Kourtzi, PhD, Alzheimer’s Research UK

Lampros Kourtis, PhD, Circadic
Rhoda Au, PhD, Boston University
Ihab Hajjar, MD, Emory University

Ioannis Tarnanas, PhD, Altoida, Inc

Jordan Glenn, PhD, Neurotrack Technologies, Inc

Christy Sheehy, PhD, C. Light Technologies, Inc

11:45

Moderator: Lampros Kourtis, PhD, Circadic

12:15

Niranjan Bose, PhD, Gates Ventures
Howard Fillit, MD, Alzheimer's Drug Discovery Foundation

12:30

End of Meeting

PROGRAM DETAILS

WELCOME NOTES

Monday, October 11, 2021
10:00 US Eastern Time

CONCLUDING REMARKS

Wednesday, October 13, 2021
12:15 US Eastern Time

Organizers/Hosts

Howard Fillit
Alzheimer’s Drug Discovery Foundation

Niranjan Bose
Gates Ventures

SESSION I

Part 1: ATN Biomarkers

PART I: This session with focus on the established biomarkers of AD pathology (amyloid, Tau and neurofilament) showcasing projects these proteins either in a stand alone test or in a combined panel.

Part 2: Ocular Approaches and Emerging Protein Biomarkers of ADRD

This session will focus on the approaches to measure proteins of interest in the eye as well understanding vasculature of different eye vessels and how they contribute to our understanding of detecting ADRD. The emerging biomarker section focusses on neuroinflammatory biomarkers and biomarkers of the contact system – all of which will aid with different diagnosis.

Robert Dean
Robert A. Dean Consulting

CO-CHAIR (Part I)

Anka G. Ehrhardt, PhD
CHDI Mgmt/CHDI Fnd.

CO-CHAIR (Part II)

Monday, October 11, 2021

10:05 – 15:30 US Eastern Time

Henrik Zetterberg
Univ of Gothenburg

Plasma Amyloid Beta Ratio as a Diagnostic Test for Alzheimer-related Amyloid Pathology

Wesley Horton
Found. for NIH

Plasma Aβ and pTau Biomarkers As Drug Development Tools to Define Clinical and Pathological Trajectories in AD

Stephen Zicha
Takeda

Plasma Aβ and pTau Biomarkers As Drug Development Tools to Define Clinical and Pathological Trajectories in AD

Kaj Blennow
Univ of Gothenburg

Tau and p-tau as Alzheimer Biomarkers – Assays, Methodological Aspects and Clinical Performance

Leyla Anderson
NeuroVision Imaging

Validation and Commercialization of a Novel Blood-based, Ultra-multiplex Laboratory Developed Test (LDT) for the Prediction of Cerebral Amyloid Status before Clinical Onset of Dementia

Manu Vandijck
FujireBio

Towards an Easy Plasma pTau 181 Detection Using the LUMIPULSE G Platform

Thomas MacGillvray
University of Edinburgh

Investigating Novel Neuro-retinal Biomarkers for Alzheimer’s Disease

Eliav Shaked
RetiSpec

RetiSpec’s Hyperspectral Imaging System: A Novel Approach to Retinal-based Detection of Alzheimer’s Disease

Catherine Bornbaum
RetiSpec

RetiSpec’s Hyperspectral Imaging System: A Novel Approach to Retinal-based Detection of Alzheimer’s Disease

Cecilia Lee
Univ. of Washington

Identifying an Ophthalmic Combinatorial Biomarker of Early Alzheimer’s Disease using Deep Learning

Erin Norris
The Rockefeller Univ.

The Role of Plasma Contact System Activation in Alzheimer’s Disease Pathophysiology

Amber Murray
Biological Dynamics

On-Chip Detection of Alzheimer’s Disease Biomarkers in Extracellular Vesicles Isolated from Peripheral Blood

Blaine Roberts
Emory University

Validation of Blood-based Biomarkers for the Detection of Brain Amyloid Accumulation

Leyla Anderson
NeuroVision Imaging

Validation of Blood-based Biomarkers for the Detection of Brain Amyloid Accumulation

Joe Phongpreecha
Stanford Univ.

Blood-based Detection of Alzheimer’s Disease through Single-Cell Peripheral Immunoprofiling

Diana Kerwin
GAP Innovations, PBC

GAP BioHermes

SESSION II

Part 1: Peripheral Molecular Biomarkers

This section will focus on emerging molecular biomarkers such as miRNA, mitochondrial DNA and epigenetic changes that will enhance our understanding of disease

Part 2: Misfolded Proteins and Biomarkers of FTD

This section focusses on misfolded proteins as well biomarkers of interest in the FTD space. These will enable selection of right patients into clinical trials, a need in the area of diseases such as FTD.

James Gallarda
Dx Consultancy

CO-CHAIR (Part 1)

Penny Dacks
AFTD

CO-CHAIR (Part 2)

Tuesday, October 12, 2021

10:00 – 15:30 US Eastern Time

Asael Lubotzky
Hebrew University

Non-invasive Detection of Brain Cell Death Using Methylation Patterns of Circulating DNA: a Novel Blood Test for Early Detection of Alzheimer’s Disease

Hüseyin Firat
Amoneta Dx

Validation of a Rapid Non-invasive Diagnostic Test to Predict MCI and early Alzheimer’s Disease

Bruno Steinkraus
Hummingbird Diagnostics

Blood-Based miRNA Diagnostics of Alzheimer’s Disease

Marta Barrachina
ADmit Therapeutics

Mitoepigenetic Analysis in Blood Samples from MCI Patients to Identify their Progression to Alzheimer’s Disease

Marta Blanch
ADmit Therapeutics

Mitoepigenetic Analysis in Blood Samples from MCI Patients to Identify their Progression to Alzheimer’s Disease

Laura Ibanez
Washington Univ

Plasma Cell-Free RNA as Alzheimer’s Disease Non-invasive Biomarker

Kira Sheinerman
Diamir Biosciences

Circulating Brain-Enriched microRNAs as Peripheral Biomarkers of Neurodegeneration

Gregory Penner
NeoNeuro

Use of Aptamarkers to Predict Brain Amyloid Deposition

Russell Lebovitz
Amprion

Advancing Differential Diagnosis of Dementias by Direct Detection of Prion Like Particles

Judith Steen
Boston Children’s Hospital

Using Large Data Approaches to Diagnose and Drug Dementia

Rachel Acuna-Narvaez
Bluefield Project to Cure FTD

The Neurofilament Surveillance Project (NSP): Lessons Learned during Year 1 of our Blood Biomarker Study in Familial Frontotemporal Lobar Degeneration

Qinwen Mao
Univ. of Utah

Plasma Pathologic TDP-43 as a Biomarker for FTLD-TDP

Wesley Horton
Found. for NIH

Analytical Validation of Neurofilament Light and Phospho-Neurofilament Heavy Biomarkers for Patient Selection in Disease Modifying Clinical Trials for Pre-Symptomatic Familial Frontotemporal Degeneration

Danielle Graham
Biogen

Analytical Validation of Neurofilament Light and Phospho-Neurofilament Heavy Biomarkers for Patient Selection in Disease Modifying Clinical Trials for Pre-Symptomatic Familial Frontotemporal Degeneration

SESSION II

Part 3: Updates from the Pacific Rim

A collection of research in ocular, digital and neuroinflammation biomarkers from investigators located in the Asia Pacific Rim.

Tetsuyuki Maruyama
Alzheimer’s Disease Data Initiative

CHAIR (Part 3)

Tuesday, October 12, 2021

18:00 – 19:15 US Eastern Time

Peter Van Wijngaarden
Ctr for Eye Res AU

Retinal Imaging Biomarkers of Alzheimer’s Disease

Matthew Pase
Monash University

Plasma Neuroinflammatory Biomarkers for the Diagnosis of Dementia Subtypes

Guoliang Xing
Chinese Univ HK

Federated Learning for Detecting Digital Biomarker of Alzheimer’s Disease

SESSION III

Digital Biomarkers

This session will showcase projects that enable the objective and quantifiable measure of psychological and behavioral changes that relate to biological changes associated with disease.